Get the Stockscreener App
6.01
0.17%
0.010
Pre-market:
5.91
-0.10
-1.66%
Novavax Inc stock is traded at $6.01, with a volume of 3.99M.
It is up +0.17% in the last 24 hours and down -20.92% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$6.00
Open:
$5.9101
24h Volume:
3.99M
Relative Volume:
0.87
Market Cap:
$1.03B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-2.6245
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
-6.24%
1M Performance:
-20.92%
6M Performance:
-40.73%
1Y Performance:
+51.39%
1-Day Range:
$5.87
$6.265
1-Week Range:
$5.81
$6.58
52-Week Range:
$3.90
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.01 | 1.03B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Preventive Vaccines Market Forecast 2025-2032- Growth - openPR.com
Novavax (NVAX) Shows Promising Vaccine Results Amid Market Stability - GuruFocus
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gaithersburg-Based Novavax’s COVID-19 Vaccine Shows Lower Side Effects Than Pfizer-BioNTech - The MoCo Show -
Lobbying Update: $50,000 of NOVAVAX INC. lobbying was just disclosed - Nasdaq
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine Formula - Yahoo Finance
At ACIP hearing, CDC says it's 'scraping' to respond to measles outbreak; FDA comments on Novavax halt - Endpoints News
Novavax vaccine shows fewer side effects in study By Investing.com - Investing.com South Africa
Here's Why Novavax (NVAX) Fell More Than Broader Market - Yahoo Finance
Novavax Inc (NVAX) Stock Price, Trades & News - GuruFocus
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
US CDC advisers begin review of vaccine guidelines after months-long delay - marketscreener.com
Novavax vaccine shows fewer side effects in study - Investing.com Australia
Novavax Says COVID-19 Vaccine Induces Fewer Symptoms Compared With Pfizer's Vaccine - marketscreener.com
Novavax (NVAX) COVID-19 Vaccine Shows Lower Reactogenicity in SH - GuruFocus
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower - GuruFocus
Shield-Utah Study Shows Novavax's Covid-19 Vaccine Induces Lower Reactogenicity Symptoms Compared To Mrna - marketscreener.com
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab - MSN
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA - The Herald Journal
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NVAX) Stock Plunges Amid Approval Delay - GuruFocus
Shares plunge after RFK Jr questions Novavax approach - The Pharma Letter
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling - MSN
Novavax (NVAX) Shares Plummet Amid Vaccine Effectiveness Concerns - GuruFocus
Novavax slides after RFK Jr. casts doubts about COVID vaccine - Yahoo Finance
Novavax (NVAX) Awaits FDA Decision Amid Vaccine Approval Delay | - GuruFocus
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer - Seeking Alpha
Novavax (NVAX) Faces Setback Amid COVID Vaccine Approval Delay - GuruFocus
Kennedy’s Comments On Novavax Delay Scientifically, Legally Inaccurate, Experts Say - insights.citeline.com
Update on Status of Novavax's COVID-19 Vaccine BLA - marketscreener.com
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy - Reuters
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot’s efficacy - KFGO
Nike, Disney, Novavax: Trending Tickers - Yahoo Finance
Vaccine Makers Fall After RFK Jr. Says Some Shots Don’t Work - MSN
Novavax (NVAX) Stock Target Lowered Amidst Vaccine Approval Conc - GuruFocus
Novavax (NVAX) Shares Plunge After RFK Jr. Questions Its Covid Vaccine Efficacy - Bloomberg.com
Sector Update: Health Care Stocks Drop Thursday Afternoon - TradingView
BofA cuts Novavax stock price target to $10 from $12 - Investing.com
Novavax & RFK Jr., Costco sales, Lovesac earnings: Market Minute - Yahoo Finance
Novavax tumbles as Kennedy raises questions over COVID vaccine - TradingView
Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine - marketscreener.com
Novavax (NVAX) Faces Stock Drop Amid FDA Vaccine Approval Delay - GuruFocus
Novavax Shares Plunge After RFK Jr. Questions Its Covid Vaccine - Bloomberg
Vaccine Makers Fall After RFK Jr. Says Some Shots Don’t Work (1) - Bloomberg Law News
Novavax in selloff after RFK Jr.’s comments on COVID vaccine - MSN
Japan approves Moderna COVID vaccine as booster, Novavax files for 1st approval - tuoitrenews.vn
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Yahoo Finance
Novavax (NasdaqGS:NVAX) Announces Leadership Change With New Board Appointments - Yahoo Finance
Novavax Inc. stock rises Wednesday, still underperforms market - MarketWatch
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):